fingolimod hydrochloride has been researched along with alpha-synuclein in 7 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Dominguez, SJ; Garza, NT; Gil-Tommee, C; Medina, D; Perez, RG; Segura-Ulate, I; Vargas-Medrano, J; Vidal-Martínez, G; Yang, B | 1 |
| Perez, RG; Segura-Ulate, I; Vargas-Medrano, J; Yang, B | 1 |
| Dagli, TC; Falkenburger, BH; Habib, P; Komnig, D; Schulz, JB; Zeyen, T | 1 |
| Diaz-Pacheco, V; Gil-Tommee, C; Miranda, JD; Najera, K; Perez, RG; Vargas-Medrano, J; Vidal-Martinez, G; Yang, B | 1 |
| Arterburn, JB; Chinnasamy, R; Perez, RG; Segura-Ulate, I; Vargas-Medrano, J; Yang, B | 1 |
| Barragan, JA; Chaparro, SA; De-Leon Esquivel, J; Diaz-Pacheco, V; Perez, RG; Segura-Ulate, I; Vargas-Medrano, J; Vidal-Martinez, G; Yang, B | 1 |
| Choudhury, SR; Karmakar, S; Sardoiwala, MN | 1 |
7 other study(ies) available for fingolimod hydrochloride and alpha-synuclein
| Article | Year |
|---|---|
FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.
Topics: Aging; alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Fingolimod Hydrochloride; Gastrointestinal Motility; Humans; Mice; Mice, Transgenic; Parkinson Disease; Protein Precursors | 2016 |
FTY720 (Fingolimod) reverses α-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells.
Topics: Acetylation; alpha-Synuclein; Animals; beta-Synuclein; Brain-Derived Neurotrophic Factor; Cells, Cultured; Down-Regulation; Fingolimod Hydrochloride; Histones; Humans; Mutation; Neuroglia; Neurons; Oligodendroglia; Rats; Valproic Acid | 2017 |
Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Dopamine; Dopaminergic Neurons; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Transgenic; MPTP Poisoning; Negative Results; Neuroprotective Agents; Parkinson Disease, Secondary; Substantia Nigra | 2018 |
FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Fingolimod Hydrochloride; Mice; Mice, Transgenic; Motor Skills; N-Acetylgalactosaminyltransferases; Parkinson Disease, Secondary; Rotarod Performance Test; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.
Topics: alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Cell Line; Ceramides; Fingolimod Hydrochloride; Glial Cell Line-Derived Neurotrophic Factor; Multiple System Atrophy; Myelin-Associated Glycoprotein; Nerve Growth Factor; Oligodendroglia; Oxidative Stress; Rats; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Humans; Inflammation; Male; Mice; Mice, Transgenic; MicroRNAs; Multiple System Atrophy; Neuroprotective Agents; Proto-Oncogene Proteins c-ret | 2020 |
Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Topics: alpha-Synuclein; Animals; Biological Availability; Cell Line, Tumor; Chitosan; Disease Models, Animal; Drug Carriers; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Proteolysis; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Ubiquitination | 2021 |